Ignite Creation Date:
2024-05-06 @ 7:19 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05974410
Status:
AVAILABLE
Last Update Posted:
2023-08-03
First Post:
2023-07-26
Brief Title:
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Sponsor:
AVM Biotechnology Inc
Organization:
AVM Biotechnology Inc
Study Overview
Official Title:
None
Status:
AVAILABLE
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
AVM Biotechnology Inc provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO As of July 2024 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma inoperablechemotherapy ineligible CNS Squamous Cell Carcinoma metastatic Breast Cancer ovarian cancer gastric cancer Hodgkins Lymphoma Mixed Phenotype Acute Myelogenous Leukemia colon cancer B-ALL Malignant Myxoid Spindle Cell Neoplasm non-small cell lung cancer DLBCL with CNS involvement metastatic prostate cancer Anaplastic T-cell Non-Hodgkins Lymphoma and metastatic pancreatic cancer Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None